Page last updated: 2024-11-06

sq-18506

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

5-Amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole: A nitrovinyl furan used as a schistosomicidal agent and proposed for trypanosomiasis, especially Chagas disease. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5284340
CHEMBL ID3252032
SCHEMBL ID7854598
SCHEMBL ID7854603
MeSH IDM0020399

Synonyms (27)

Synonym
28754-68-9
trans-5-amino-3[2-(5-nitro-2-furyl)vinyl]-1,2,4-oxadiazole
3-[(e)-2-(5-nitrofuran-2-yl)ethenyl]-1,2,4-oxadiazol-5-amine
sq 18506
trans-5-amino-3-(2-(5-nitro-2-furyl)-vinyl)-1,2,4-oxadiazole
ai3-27918
sq-18506
sq18506
ccris 5440
1,2,4-oxadiazol-5-amine, 3-(2-(5-nitro-2-furanyl)ethenyl)-, (e)-
(e)-5-amino-3-(2-(5-nitro-2-furanyl)ethenyl)-1,2,4-oxadiazole
1,2,4-oxadiazole, 5-amino-3-(2-(5-nitro-2-furyl)vinyl)- (e)-
5-amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole
3-[(e)-2-(5-nitro-2-furyl)vinyl]-1,2,4-oxadiazol-5-amine
1,2,4-oxadiazol-5-amine, 3-[(e)-2-(5-nitro-2-furanyl)ethenyl]-
brn 1079486
b5j6s26xce ,
unii-b5j6s26xce
CHEMBL3252032
SCHEMBL7854598
SCHEMBL7854603
DTXSID1020061
Q63088098
trans-5-amino-3-(2-(5-nitro-2-furyl)vinyl)-1,2,4-oxadi-azole
25333-00-0
1,2,4-oxadiazol-5-amine, 3-((1e)-2-(5-nitro-2-furanyl)ethenyl)-
trans-5-amino-3-((5-nitro-2-furyl)vinyl)-1,2,4-oxadiazole

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Animals infected parenterally with Streptococcus pyogenes, Proteus mirabilis, Mycobacterium tuberculosis, and Candida albicans, or topically with Trichophyton mentagrophytes, did not respond to therapy with the drug at the dosage levels used."( New antimicrobial nitrofuran, trans-5-amino-3-[2-(5-nitro-2-furyl)vinyl]-delta2-1,2,4-oxadiazole: antimicrobial efficacy in mice, rats, and guinea pigs.
Gadebusch, HH; McRipley, RJ; Pansy, F; Semar, R, 1974
)
0.25
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID1132880Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 104 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1132885Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood intramuscularly treated daily from day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1132886Potency index, ratio of nifurtimox SD90 to compound SD90 for Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood1977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1132882Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 26 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
AID1132884Antitrypanosomal activity against Trypanosoma cruzi infected in albino CF1 mouse assessed as reduction in number of parasites in blood at 3.25 mg/kg/day, intramuscular treatment started on day 10 of infection up to day 141977Journal of medicinal chemistry, Jun, Volume: 20, Issue:6
In search of anti-Trypanosoma cruzi drugs: new leads from a mouse model.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (19)

TimeframeStudies, This Drug (%)All Drugs %
pre-199019 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other19 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]